Puma Biotechnology
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00781430
- Locations
- ๐ท๐บ
Pfizer Investigational Site, Moscow, Russian Federation
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT00777101
- Locations
- ๐ฟ๐ฆ
The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa
๐น๐ญDivision of Medical Oncology, Department of Medicine, Bangkok-noi, Bangkok, Thailand
๐ฌ๐งBroomfield Hospital, Chelmsford, Essex, United Kingdom
Study Evaluating Safety And Tolerability, Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00768469
- Locations
- ๐ฏ๐ต
Investigational Site, Tokyo, Japan
Study Evaluating The Tolerability Of Multiple Doses Of HKI-272
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00757809
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00741260
- Locations
- ๐ฆ๐บ
Border Medical Oncology, Wodonga, Victoria, Australia
๐ญ๐ทUniversity Hospital Center Zagreb Department of Oncology, Zagreb, Croatia
๐ท๐บSaint-Petersburg State Medical University n.a. acad. I.P. Pavlov, Laboratory of Thoracic Oncology of Pulmonology Research Institute, Saint Petersburg, Russian Federation
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00708903
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT00706030
- Locations
- ๐บ๐ธ
Albert Einstein Cancer Center, Bronx, New York, United States
๐ซ๐ทCentre Paul Papin, Angers, France
๐ช๐ธCentro Oncologico de Galicia, A Coruรฑa, Spain
Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00550212
Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects
- Conditions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00498745
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00445458
- Locations
- ๐บ๐ธ
Boston University Medical Center, Boston, Massachusetts, United States
๐บ๐ธMid-Michigan Physicians-HOS Division, Lansing, Michigan, United States
๐จ๐ฆPrincess Margaret Hospital University Health Network, Toronto, Ontario, Canada